Latest & greatest articles for valsartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on valsartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on valsartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for valsartan

21. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction.

Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Background: Sacubitril-valsartan therapy reduces cardiovascular mortality compared with enalapril therapy in patients with heart failure with reduced ejection fraction. Objective: To evaluate the cost-effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patients with chronic heart failure. Design: Markov decision model. Data Sources: Clinical (...) trials, observational analyses, reimbursement data from the Centers for Medicare & Medicaid Services, drug pricing databases, and Centers for Disease Control and Prevention life tables. Target Population: Patients at an average age of 64 years, New York Heart Association (NYHA) class II to IV heart failure, and left ventricular ejection fraction of 0.40 or less. Time Horizon: Lifetime. Perspective: Societal. Intervention: Treatment with sacubitril-valsartan or lisinopril. Outcome Measures: Life

Annals of Internal Medicine2016

22. Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study

Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study 27747834 2018 11 13 2199-1154 3 3 2016 Sep Drugs - real world outcomes Drugs Real World Outcomes Real-life Effectiveness and Safety of Amlodipine/Valsartan Single-pill Combination in Patients with Hypertension in Egypt: Results from the EXCITE Study. 307-315 EXCITE (clinical experience of amlodipine and valsartan in hypertension) evaluated the (...) real-world effectiveness and safety of single-pill combinations (SPCs) of amlodipine/valsartan (Aml/Val) and amlodipine/valsartan/hydrochlorothiazide (Aml/Val/HCTZ) in patients with hypertension from the Middle East and Asia. The objective of this study was to report the results of EXCITE study from Egypt, where all patients were prescribed Aml/Val. This was a 26-week, observational, multicenter, prospective, non-interventional, open-label study. Effectiveness was assessed as change in the mean

Drugs - real world outcomes2016 Full Text: Link to full Text with Trip Pro

23. [Sacubitril/valsartan: addendum to commission A15-60]

[Sacubitril/valsartan: addendum to commission A15-60] Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29 [Sacubitril/valsartan: addendum to commission A15-60] Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29 [Sacubitril/valsartan: addendum to commission A15-60] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation (...) of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sacubitril/Valsartan: addendum zum auftrag A15-60; auftrag A16-29. [Sacubitril/valsartan: addendum to commission A15-60] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 394. 2016 Final publication URL Indexing Status Subject indexing assigned by CRD MeSH Humans; Tetrazoles; Valine; Valsartan Language Published

Health Technology Assessment (HTA) Database.2016

24. [Sacubitril/valsartan - benefit assessment]

[Sacubitril/valsartan - benefit assessment] Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60 [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60 [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Record Status This is a bibliographic record (...) of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen. Sacubitril/valsartan: nutzenbewertung gemäß § 35a SGB V; dossierbewertung; auftrag A15-60. [Sacubitril/valsartan - benefit assessment according to §35a Social Code Book V] Cologne: Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen (IQWiG). IQWiG-Berichte 379. 2016

Health Technology Assessment (HTA) Database.2016

25. Neparvis (sacubitril / valsartan) - heart failure

Neparvis (sacubitril / valsartan) - heart failure 1 April 2016 EMA/255018/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment Report Neparvis International non-proprietary name: sacubitril / valsartan Procedure No. EMEA/H/C/004343/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 (...) CLCZ696B2314 (also known as PARADIGM-HF) was designed to accomplish this purpose. LCZ696 (sacubitril/valsartan, Neparvis) is a novel therapy proposed for treatment of heart failure (HF) (New York Heart Association (NYHA) class II-IV) in patients with systolic dysfunction (reduced ejection fraction, HFrEF). Following oral administration, LCZ696 dissociates into valsartan and the pro-drug sacubitril (also known as AHU377, a new molecular entity), which is further metabolized to the neprilysin inhibitor

European Medicines Agency - EPARs2016

26. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction Sacubitril valsartan for treating Sacubitril valsartan for treating symptomatic chronic heart failure with symptomatic chronic heart failure with reduced ejection fr reduced ejection fraction action T echnology appraisal guidance Published: 27 April 2016 nice.org.uk/guidance/ta388 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388) © NICE 2018. All rights reserved. Subject to Notice of rights (https

National Institute for Health and Clinical Excellence - Technology Appraisals2016

27. Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension.

Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan) in Patients with Stage 1 or 2 Essential Hypertension. 27122680 2016 04 28 2016 04 28 2017 02 20 1011-6842 29 1 2013 Jan Acta Cardiologica Sinica Acta Cardiol Sin Effect of 8-Week Combination Therapy with an Extended-Release α1-Blocker (Bunazosin or Doxazosin) in Inadequate Responders to an Angiotensin II Antagonist (Valsartan (...) ) in Patients with Stage 1 or 2 Essential Hypertension. 11-8 Given the favorable impact of α1-blockers on lipid and glucose metabolism, this study was designed to compare the efficacy of two extended-release α1-blockers (bunazosin and doxazosin) as an add-on treatment in subjects with stage 1 or 2 essential hypertension which was inadequately controlled by valsartan 80 mg/day. After a 5-week treatment of valsartan monotherapy, subjects with inadequately controlled hypertension were randomized to receive

Zhonghua Minguo xin zang xue hui za zhi = Acta Cardiologica Sinica2016

28. Amlodipine / Valsartan Mylan - hypertension

Amlodipine / Valsartan Mylan - hypertension 28 January 2016 EMA/CHMP/182030/2016 Committee for Medicinal Products for Human Use (CHMP) Assessment report Amlodipine/Valsartan Mylan International non-proprietary name: amlodipine / valsartan Procedure No. EMEA/H/C/004037/0000 Note Assessment report as adopted by the CHMP with all information of a commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone (...) /National Formulary UV Ultraviolet light Assessment report EMA/CHMP/182030/2016 Page 4/31 1. Background information on the procedure 1.1. Submission of the dossier The applicant MYLAN S.A.S. submitted on 20 January 2015 an application for Marketing Authorisation to the European Medicines Agency (EMA) for Amlodipine/Valsartan Mylan, through the centralised procedure under Article 3 (3) of Regulation (EC) No. 726/2004 – ‘Generic of a Centrally authorised product’. The eligibility to the centralised

European Medicines Agency - EPARs2016

29. Sacubitril/valsartan (Entresto) - in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction

Sacubitril/valsartan (Entresto) - in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction

Scottish Medicines Consortium2016

30. PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure

PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure RXFILES PRELIMINARY TRIAL SUMMARY LYNETTE KOSAR JAN 7 TH , 2015 – WWW.RXFILES.CA Page 1 of 3 PARADIGM-HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in HF 1 Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality & morbidity in HF BOTTOM LINE ? In PARADIGM-HF, clinically stable patients with heart failure (HF) (NYHA class I 5%, class (...) : LCZ696 375±71mg (=valsartan 300±57mg/day), Enalapril 18.9±3.4mg - MEAN SBP AT 8 MONTHS: LCZ696 3.2±0.4mmHg lower (p<0.001), but the authors stated this was not the reason for benefit when it was analyzed as a time-dependent covariate STRENGTHS, LIMITATIONS, & UNCERTAINTIES STRENGTHS: ? Important clinical endpoints (e.g. cardiovascular death, HF hospitalizations) with blinded adjudication of outcomes. ? Only 20 patients lost to follow-up (0.13%). LIMITATIONS: ? No Phase II studies have been conducted

RxFiles2016

31. LCZ696 (Sacubitril/ Valsartan) ENTRESTO Summary and Practical Tips

LCZ696 (Sacubitril/ Valsartan) ENTRESTO Summary and Practical Tips November 2015 LCZ696 (Sacubitril/Valsartan), Entresto TM Summary and Practical Tips Mechanism of action: sacubitril is a neprilysin (endopeptidase) inhibitor: ?vasodilatory peptides ? ?sodium loss, ?hypertrophy/remodeling. Combination with an ARB is necessary as inhibition of neprilysin leads to activation of the renin angiotensin aldosterone system (RAAS). Indication: • Health Canada Indication 1 : heart failure with reduced (...) ejection fraction (HFrEF), NYHA class II-III, in combination with other heart failure (HF) therapies in place of an ACEI or ARB • CCS HF 2014 Guidelines 2 : mild-moderate HF, left ventricular ejection fraction (LVEF) 5.2 mmol/L • History of angioedema Dosing: • Tablet: film-coated, unscored containing both sacubitril and valsartan (dose is sum of agents) • Strengths: 50 mg (24/26mg; white), 100 mg (49/51mg; yellow), 200 mg (97/103mg; pink) o Note: different valsartan salts; Entresto TM valsartan 103mg

RxFiles2016

32. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan.

Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. - PubMed - NCBI Warning: The NCBI web site requires JavaScript to function. Search database Search term Search Result Filters Format Summary Summary (text) Abstract Abstract (text) MEDLINE XML PMID List Apply Choose Destination File Clipboard Collections E-mail Order My Bibliography Citation manager Format Create File 1 selected item: 26630151 Format MeSH (...) and Other Data E-mail Subject Additional text E-mail Add to Clipboard Add to Collections Order articles Add to My Bibliography Generate a file for use with external citation management software. Create File 2015 Dec 3;373(23):2289-90. doi: 10.1056/NEJMc1509753. Estimating the Long-Term Treatment Benefits of Sacubitril-Valsartan. 1 , , , , , , , , , ; . 1 Brigham and Women's Hospital, Boston, MA. PMID: 26630151 DOI: [Indexed for MEDLINE] Free full text Publication type MeSH terms Substances Full Text

NEJM2015

34. Sacubitril/valsartan (TBC)

Sacubitril/valsartan (TBC) Sacubitril/valsartan | CADTH.ca Find the information you need Sacubitril/valsartan Sacubitril/valsartan Last Updated: August 4, 2015 Result type: Reports Project Number: SR0447-000 Product Line: Generic Name: Sacubitril/valsartan Brand Name: Entresto Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Heart failure, NYHA class II or III Submission Type: New Project Status: Active Date Recommendation Issued: March 18, 2016 Recommendation Type: List

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2015

35. Sacubitril/valsartan (TBC)

Sacubitril/valsartan (TBC) Sacubitril/valsartan | CADTH.ca Find the information you need Sacubitril/valsartan Sacubitril/valsartan Last Updated: August 4, 2015 Result type: Reports Project Number: SR0447-000 Product Line: Generic Name: Sacubitril/valsartan Brand Name: Entresto Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Heart failure, NYHA class II or III Submission Type: New Project Status: Active Date Recommendation Issued: March 18, 2016 Recommendation Type: List

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2015

36. Sacubitril/valsartan (TBC)

Sacubitril/valsartan (TBC) Sacubitril/valsartan | CADTH.ca Find the information you need Sacubitril/valsartan Sacubitril/valsartan Last Updated: August 4, 2015 Result type: Reports Project Number: SR0447-000 Product Line: Generic Name: Sacubitril/valsartan Brand Name: Entresto Manufacturer: Novartis Pharmaceuticals Canada Inc. Indications: Heart failure, NYHA class II or III Submission Type: New Project Status: Active Date Recommendation Issued: March 18, 2016 Recommendation Type: List

Canadian Agency for Drugs and Technologies in Health - Common Drug Review2015

37. Entresto (sacubitril / valsartan) - To treat heart failure

Entresto (sacubitril / valsartan) - To treat heart failure ENTRESTO (sacubitril/valsartan) Tablets U.S. Department of Health and Human Services Search FDA Submit search ENTRESTO (sacubitril/valsartan) Tablets ENTRESTO Company: Novartis Pharmaceuticals Corp. Application No.: 207620 Approval Date: 07/07/2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2015

38. Entresto - sacubitril / valsartan

Entresto - sacubitril / valsartan 24 September 2015 EMA/671279/2015 Committee for Medicinal Products for Human Use (CHMP) Assessment report Entresto International non-proprietary name: SACUBITRIL / VALSARTAN Procedure No. EMEA/H/C/004062/0000 Note Assessment report as adopted by the CHMP with all information of commercially confidential nature deleted. 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (...) titration Ki Equilibrium dissociation constant for an enzyme inhibitor KIM-1 Kidney injury molecule-1 Assessment report EMA/671279/2015 Page 6/115 LBQ657 ctive metabolite of sacubitril, a neprilysin inhibitor LC-MS/MS Liquid chromatography – tandem mass spectrometry LCZ696 sacubitril/valsartan LCZ696-ABA LCZ696 sodium salt hydrate, crystal modification A LD50 Lethal dose, 50% LOQ Limit of quantification LSM Least square mean LVEF Left-ventricular ejection fraction MA Marketing Authorisation MAH

European Medicines Agency - EPARs2015

39. CardioMEMS HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto, Novartis AG) for Management of Congestive Heart Failure

CardioMEMS HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto, Novartis AG) for Management of Congestive Heart Failure ©Institute for Clinical and Economic Review, 2015 CardioMEMS™ HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto™, Novartis AG) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks Final Report December 1, 2015 Completed by: Institute for Clinical and Economic Review ©Institute for Clinical (...) and associated software for monitoring increases in pulmonary artery (PA) pressure (a key indicator of worsening CHF) known as the CardioMEMS™ HF System (St. Jude Medical), and a drug, Entresto™ (Novartis AG), a combination of the angiotensin II receptor blocker (ARB) valsartan and the neprilysin (nep-ri- li-sin) inhibitor sacubitril. The objective of this report is to evaluate the accumulated evidence on these two new interventions, to understand the context around their potential use in clinical practice

California Technology Assessment Forum2015

40. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.

Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. 24881993 2014 06 02 2014 06 10 2016 10 18 1474-547X 383 9932 2014 May 31 Lancet (London, England) Lancet Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study. 1889-98 10.1016/S0140-6736(14)60614-0 S0140-6736(14)60614-0 The fixed-dose combination of any two antihypertensive drugs from different drug classes (...) is typically more effective in reducing blood pressure than a dose increase of component monotherapy. We assessed the efficacy and safety of a fixed-dose combination of a vasodilating β blocker (nebivolol) and an angiotensin II receptor blocker (valsartan) in adults with hypertension. We did an 8-week, phase 3, multicentre, randomised, double-blind, placebo-controlled, parallel-group trial at 401 US sites. Participants (age ≥18 years) with hypertension but with blood pressure less than 180/110 mm Hg were

Lancet2014